Media

Washington, D.C. – Representative Gus Bilirakis, Vice-Chairman of the House Committee on Veterans' Affairs, today testified before the House Veterans' Affairs' Subcommittee on Health about his bill, the Creating Options for Veterans' Expedited Recovery (COVER) Act. Bilirakis' bipartisan legislation will establish a commission to examine VA's current therapy model and the potential benefits in incorporating complementary alternative therapies.

U.S. Rep. Gus Bilirakis, R-Fla., was honored by the U.S. Travel Association on Wednesday with its "Distinguished Travel Champion Award." Bilirakis was joined by U.S. Commerce Secretary Penny Prtitzker; U.S. Sen. John Thune, R-S.D.; U.S. Sen. Amy Klobuchar, D-Minn.; and U.S. Rep. Mike Quigley, D-Ill.

Washington, D.C. – Congressman Gus Bilirakis (R-FL), member of the Energy and Commerce Committee's Health Subcommittee, today vote in favor of H.R. 2, the Medicare Access and CHIP Reauthorization Act (MACRA), to repeal and replace the Sustainable Growth Rate (SGR) formula. The bill was passed by a vote of 392 to 37. The bill will replace the SGR with a Merit-Based Incentive Payment System – MIPS – which will pay doctors based on quality, not volume.

Washington, D.C. – Representative Gus Bilirakis (R-FL), a member of the Energy and Commerce Committee's Subcommittee on Communications and Technology, today questioned FCC Commissioners regarding the impending closing of the FCC's Tampa Bay Field Office.

Washington, D.C. – Yesterday, Congressman Gus Bilirakis (R-FL) joined Rare Disease Caucus Co-Chair Congressman Lance (R-NJ) and Congressman Garamendi (D-CA) at a bipartisan press conference with Noah Coughlan of Vacaville, California. Mr. Coughlan is currently running across America to raise awareness about rare diseases. Congressman Bilirakis and Mr.

Washington, D.C. – Representative Gus Bilirakis (R-FL), today introduced H.R. 1353, the Promoting Access for Treatments Ideal in Enhancing New Therapies (PATIENT) Act, with his colleagues Representative Gerry Connolly (D-VA), Representative Morgan Griffith (R-VA), and Representative Steven Israel (D-NY). The PATIENT Act would incentivize drug manufacturers by allowing for an additional 24 months of market exclusivity for a medication, if they are able to improve a medication to create FDA-approved new therapeutic entities.

Washington, D.C. – Representative Gus Bilirakis (R-FL), released the following statement on funding the Department of Homeland Security (DHS) and the President's Executive Action on immigration: